Table 3.
Overview of (significant) PSMs, and continence and potency preserved at last follow‐up per participating centre and in total.
| St. Vincent’s Prostate Cancer Centre | Instituto Valenciano de Oncologia | St. Antonius Hospital | Amsterdam University Medical Centres | Total | Missing, n (%) | |
|---|---|---|---|---|---|---|
| Primary IRE treatments performed, n | 248 | 58 | 30 | 29 | 365 | – |
| sRP performed, n (%) | 22/248 (8.9) | 4/58 (6.9) | 5/30 (16.7) | 8/29 (27.6) | 39/365 (10.7) | – |
| PSMs, n (%) | 2/22 (9.1) | 2/4 (50) | 2/5 (40) | 4/8 (50) | 10/39 (25.6) | 0 (0) |
| Significant PSMs, n (%) | 0/22 (0) | 2/4 (50) | 0/5 (0) | 4/8 (50) | 6/39 (15.4) | 0 (0) |
| Continence, n (%) | 20/20 (100) | 2/4 (50) | 4/4 (100) | 8/8 (100) | 34/36 (94.4) | 3 (7.7) |
| Potency, n (%) | 11/18 (61.1) | 3/4 (75) | 1/5 (20) | 3/7 (42.9) | 18/34 (52.9) | 2 (5.1) |
| Follow‐up, months, median (IQR) | 19.6 (17.1–28.5) | 15.8 (12.2–21.1) | 17.7 (12–20.3) | 19.7 (11.5–38.6) | 17.7 (11.8–26.4) | – |
A significant PSM is considered as >5 mm cancer core length and/or ISUP GG ≥2. Patients were considered continent when requiring 0–1 pads/day and potency was described as erections firm enough for sexual intercourse with or without PDE‐5‐inhibitor.